Bajaj Healthcare's Q1 FY27 revenue grew 11.3% to Rs. 165.6 Cr, with PAT up 15.8% to Rs. 13.7 Cr.

Domestic API sales surged 27%. A key milestone for Cenobamate Tablets, a next-gen anti-seizure drug, was secured.

An expanded R&D centre is now operational.